Watch DNTH. Know when insiders buy.
One email the day a filing lands. Free.
Work order
37
FLAG · insiders 25, shorts 49
Insiders, 90 days
−$2.5M
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6BP/E —DIV YIELD —FCF YIELD -2.58%REV TTM —NET INCOME −$192.2MNET CASH —52W 31.80 – 115.96SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$61.5M | −$50.2M | — | -0.90 | −$49M | $181K | −$49.2M | Aug 4 |
| Q1 2026 · Mar 31 | — | — | — | −$46.5M | −$40.8M | — | -0.85 | −$28.9M | $10K | −$28.9M | Aug 4 |
| Q4 2025 · Dec 31derived | $284K | −78.6% | — | −$69.5M | −$64.4M | — | -1.52 | −$47M | $138K | −$47.1M | Mar 9 |
| Q3 2025 · Sep 30 | $396K | −81.8% | — | −$40.3M | −$36.8M | — | -0.97 | −$30.6M | $5K | −$30.6M | Nov 5 |
| Q2 2025 · Jun 30 | $193K | −89.6% | — | −$34.9M | −$31.6M | — | -0.88 | −$23.9M | $46K | −$23.9M | Aug 4 |
| Q1 2025 · Mar 31 | $1.2M | +33.1% | — | −$33.2M | −$29.5M | — | -0.82 | −$27.6M | $24K | −$27.7M | Aug 4 |
| Q4 2024 · Dec 31derived | $1.3M | +190.2% | — | −$31.9M | −$28.4M | — | -0.82 | −$27.4M | $31K | −$27.5M | Mar 9 |
| Q3 2024 · Sep 30 | $2.2M | +135.1% | — | −$29.9M | −$25.2M | — | -0.74 | −$21.3M | $25K | −$21.3M | Nov 5 |
| Q2 2024 · Jun 30 | $1.9M | — | — | −$22.2M | −$17.6M | — | -0.51 | −$14.5M | $17K | −$14.5M | Nov 5 |
| Q1 2024 · Mar 31 | $874K | — | — | −$17.8M | −$13.7M | — | -0.54 | −$14.9M | $32K | −$15M | Nov 5 |
| Q4 2023 · Dec 31derived | $457K | — | — | −$13M | −$10.6M | — | 8.95 | −$11.9M | $10K | −$11.9M | Mar 11 |
| Q3 2023 · Sep 30 | $924K | — | — | −$15.8M | −$14.8M | — | -3.78 | −$10M | −$145K | −$9.8M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2M | — | −$177.9M | −$162.3M | -7973.3% | -4.20 | −$129.1M | $213K | −$129.3M | — | — |
| FY2024 · to Dec 31 | $6.2M | — | −$101.9M | −$85M | -1362.8% | -2.55 | −$78.2M | $105K | −$78.3M | — | — |
| FY2023 · to Dec 31 | $2.8M | — | −$48.2M | −$43.6M | -1541.2% | -8.45 | −$36.9M | $110K | −$37M | — | — |
| FY2022 · to Dec 31 | — | — | −$29.7M | −$28.5M | — | -32.57 | −$29.1M | $314K | −$29.4M | — | — |
| FY2021 · to Dec 31 | — | — | −$74.7M | −$71.1M | — | -1.29 | −$59.5M | $1.3M | −$60.8M | — | — |
| FY2020 · to Dec 31 | — | — | −$78.7M | −$74.9M | — | -1.71 | −$64M | $400K | −$64.4M | — | — |
Every number comes from Dianthus Therapeutics, Inc. /DE/'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.